Adding malavero to c-art does not improve the clinical outcome of HIV infection
-
Last Update: 2020-02-17
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
In a new double-blind randomized controlled clinical trial, researchers from France, Spain and Italy found that adding maraviroc to the standard combination antiretroviral drugs (c-art) did not seem to improve the clinical results of patients with advanced HIV infection who started treatment The related research results were published in the Journal of annals of internal medicine on February 11, 2020, under the title of "addition of maraviroc versus placebo to standard antiretroviral therapy for initial treatment of advanced HIV infection: a standardized trial" In resource rich countries, one-third of HIV patients are diagnosed late These patients with advanced HIV infection face a greater risk of AIDS identified events and death due to opportunistic infection, which may be related to decreased immunity Malavero, an antiretroviral drug with immunological effects, may benefit such patients The researchers randomly assigned 416 HIV positive adults who were first treated with c-art to begin treatment with c-art plus placebo or c-art plus malavero for 72 weeks to assess the benefits of adding malavero to standard c-art treatment They found that in three European countries, the incidence of serious diseases was 11.2 per 100 person years among people diagnosed with advanced HIV infection, and for these patients, the addition of malavero to standard c-art had no effect on this value At week 48, use of malavero was associated with a higher risk of viral failure, but not at week 72 The increase in CD4 T cell count was similar in both groups throughout the study, but the increase in CD4-CD8 ratio was lower in the malavero group The researchers concluded that there did not appear to be any clinical benefit to adding malavero to patients diagnosed with advanced HIV infection.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.